A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

NCT02550535 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukaemia (AML)

Interventions

GENETIC: Autologous WT1 TCR transduced T cells

Sponsor

Cell Medica Ltd

Collaborators

[object Object]
[object Object]